Treatment of cognitive dysfunction in major depressive disorder-a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine

被引:64
|
作者
Pehrson, Alan L. [1 ]
Leiser, Steven C. [2 ]
Gulinello, Maria [3 ]
Dale, Elena [2 ]
Li, Yan [1 ]
Waller, Jessica A. [1 ]
Sanchez, Connie [1 ]
机构
[1] Lundbeck Res USA Inc, External Sourcing & Sci Excellence, Paramus, NJ 07652 USA
[2] Landbeck Res USA Inc, Bioanal & Physiol, Paramus, NJ 07652 USA
[3] Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA
关键词
Major depressive disorder; Cognitive function; Vortioxetine; Lu AA21004; Electrophysiology; Receptor occupancy; MEDIAL PREFRONTAL CORTEX; CHRONIC MILD STRESS; ADULT HIPPOCAMPAL NEUROGENESIS; ELDERLY GENERAL-POPULATION; ACUTE TRYPTOPHAN DEPLETION; LU AA21004; SYNAPTIC PLASTICITY; ALZHEIMERS-DISEASE; QUANTITATIVE EEG; TREATMENT INCREASES;
D O I
10.1016/j.ejphar.2014.07.044
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although major depressive disorder is primarily considered a mood disorder, depressed patients commonly present with clinically significant cognitive dysfunction that may add to their functional disability. This review paper summarizes the available preclinical data on the effects of antidepressants, including monoamine reuptake inhibitors and the multimodal antidepressant vortioxetine, in behavioral tests of cognition such as cognitive flexibility, attention, and memory, or in potentially cognition-relevant mechanistic assays such as electroencephalography, in vivo microdialysis, in vivo or in vitro electrophysiology, and molecular assays related to neurogenesis or synaptic sprouting. The available data are discussed in context with clinically relevant doses and their relationship to target occupancy levels, in order to evaluate the translational relevance of preclinical doses used during testing. We conclude that there is preclinical evidence suggesting that traditional treatment with monoamine reuptake inhibitors can induce improved cognitive function, for example in cognitive flexibility and memory, and that the multimodal-acting antidepressant vortioxetine may have some advantages by comparison to these treatments. However, the translational value of the reviewed preclinical data can be questioned at times, due to the use of doses outside the therapeutically-relevant range, the lack of data on target engagement or exposure, the tendency to investigate acute rather than long term antidepressant administration, and the trend towards using normal rodents rather than models with translational relevance for depression. Finally, several suggestions are made for advancing this field, including expanded use of target occupancy assessments in preclinical and clinical experiments, and the use of translationally valuable techniques such as electroencephalography. (C) 2014 The Authors. Published by Elsevier B.V.
引用
收藏
页码:19 / 31
页数:13
相关论文
共 39 条
  • [21] A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine
    Montgomery, Stuart A.
    Nielsen, Rebecca Z.
    Poulsen, Lis H.
    Haggstrom, Lars
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2014, 29 (05) : 470 - 482
  • [22] Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland
    Benedict, Agnes
    Arellano, Jorge
    De Cock, Erwin
    Baird, Jessamy
    JOURNAL OF AFFECTIVE DISORDERS, 2010, 120 (1-3) : 94 - 104
  • [23] Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability
    Xu, Y.
    Bai, S. J.
    Lan, X. H.
    Qin, B.
    Huang, T.
    Xie, P.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2016, 49 (06)
  • [24] Melancholic features and treatment outcome to selective serotonin reuptake inhibitors in major depressive disorder: A re-analysis of the STAR*D trial
    Szmulewicz, Alejandro
    Valerio, Marina P.
    Lomastro, Julieta
    Martino, Diego J.
    JOURNAL OF AFFECTIVE DISORDERS, 2024, 347 : 101 - 107
  • [25] Therapy Effects on Working Ability by Venlafaxine Compared to Serotonin Reuptake Inhibitors in the Treatment of Major Depressive Disorder of Different Severity
    Schmitt, A. B.
    Volz, H. -P.
    Wiedemann, K.
    Fritze, J.
    Loeschmann, P. -A.
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2008, 13 (05): : 269 - 275
  • [26] Factor analysis of electroacupuncture and selective serotonin reuptake inhibitors for major depressive disorder: an 8-week controlled clinical trial
    Yang, Xinjing
    Gong, Weijun
    Ma, Xuehong
    Wang, Sihan
    Wang, Xueqin
    Guo, Tianwei
    Guo, Zhuo
    Sun, Yang
    Li, Jing
    Zhao, Bingcong
    Tu, Ya
    ACUPUNCTURE IN MEDICINE, 2020, 38 (01) : 45 - 52
  • [27] Tolerability of vortioxetine compared to selective serotonin reuptake inhibitors in older adults with major depressive disorder (VESPA): a randomised, assessor-blinded and statistician-blinded, multicentre, superiority trial
    Ostuzzi, Giovanni
    Gastaldon, Chiara
    Tettamanti, Mauro
    Cartabia, Massimo
    Monti, Igor
    Aguglia, Andrea
    Aguglia, Eugenio
    Bartoli, Francesco
    Callegari, Camilla
    Canozzi, Andrea
    Carbone, Elvira Anna
    Carra, Giuseppe
    Caruso, Rosangela
    Cavallotti, Simone
    Chiappini, Stefania
    Colasante, Fabrizio
    Compri, Beatrice
    D'Agostino, Armando
    De Fazio, Pasquale
    de Filippis, Renato
    Gari, Matteo
    Ielmini, Marta
    Ingrosso, Gianmarco
    Mammarella, Silvia
    Martinotti, Giovanni
    Rodolico, Alessandro
    Roncone, Rita
    Sterzi, Enrico
    Tarsitani, Lorenzo
    Tiberto, Elisa
    Todini, Liliana
    Amaddeo, Francesco
    D'Avanzo, Barbara
    Barbato, Angelo
    Barbui, Corrado
    ECLINICALMEDICINE, 2024, 69
  • [28] Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: An open-label, uncontrolled study
    Kaplan, EM
    CLINICAL THERAPEUTICS, 2002, 24 (07) : 1194 - 1200
  • [29] Association of Serum Biomarker Levels and BDNF Gene Polymorphism with Response to Selective Serotonin Reuptake Inhibitors in Indian Patients with Major Depressive Disorder
    Ramesh, Varsha
    Venkatesan, Vettriselvi
    Chellathai, Darling
    Silamban, Santhi
    NEUROPSYCHOBIOLOGY, 2021, 80 (03) : 201 - 213
  • [30] Dose-Response Relationship in Selective Serotonin and Norepinephrine Reuptake Inhibitors in the Treatment of Major Depressive Disorder: A Meta-Analysis and Network Meta-Analysis of Randomized Controlled Trials
    Rink, Lena
    Adams, Anne
    Braun, Cora
    Bschor, Tom
    Kuhr, Kathrin
    Baethge, Christopher
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2022, 91 (02) : 84 - 93